Figure 3.

Kinetics of CXCR3 ligand mRNA synthesis are similar in murine and human immune system. (A) Splenocytes from naive BALB/c mice were mixed with splenocytes isolated from DUC18 mice. Mixed splenocytes were incubated with mERK2–9m peptide, wERK2–9m peptide or DMSO as a control. The relative fold increase of mRNA levels of murine CXCL9 compared with the DMSO control was quantified by RT-qPCR at the indicated time points. (B) CHP-NY-ESO-1 was subcutaneously injected into the back of BALB/c mice, twice at a 1-week interval. Splenic cells from pooled spleens (n = 3 per experiment) were prepared for analysis 7 d after the second immunization. Pooled splenic cells from naive BALB/c (left) or immunized BALB/c (right) mice were incubated with one of 17 overlapping peptides spanning the whole amino acid sequence of NY-ESO-1 (Table S1) or DMSO as a control for 8 h. Total RNA was extracted, and the relative fold increase of mRNA levels of murine CXCL9 compared with DMSO was quantified.